PensionDanmark Pensionsforsikringsaktieselskab increased its stake in Zoetis Inc. (NYSE:ZTS – Free Report) by 13.4% during the second quarter, Holdings Channel reports. The firm owned 147,182 shares of the company’s stock after acquiring an additional 17,340 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Zoetis were worth $10,576,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. grew its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after buying an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP raised its position in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. State Street Corp lifted its holdings in shares of Zoetis by 0.8% during the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after acquiring an additional 149,382 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after acquiring an additional 189,235 shares during the period. Finally, Norges Bank acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $734,425,000. Institutional investors own 92.80% of the company’s stock.
Zoetis Price Performance
ZTS stock opened at $72.53 on Friday. The stock has a market cap of $30.41 billion, a price-to-earnings ratio of 11.95, a P/E/G ratio of 1.34 and a beta of 0.74. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The company has a 50 day simple moving average of $76.66 and a 200 day simple moving average of $100.75. Zoetis Inc. has a 1 year low of $71.47 and a 1 year high of $160.48.
Zoetis Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. Zoetis’s payout ratio is currently 35.16%.
Insiders Place Their Bets
In other news, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction on Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the acquisition, the director directly owned 21,458 shares in the company, valued at approximately $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was purchased at an average price of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 11,650 shares of company stock valued at $886,384 in the last 90 days. Corporate insiders own 0.22% of the company’s stock.
Key Zoetis News
Here are the key news stories impacting Zoetis this week:
- Positive Sentiment: Zoetis reported second-quarter adjusted earnings of $1.87 per share, above the $1.84–$1.85 analyst consensus and up from $1.76 a year earlier. The earnings beat provides some support for the stock. Zoetis Surpasses Q2 Earnings Estimates
- Positive Sentiment: JPMorgan lowered its price target from $130 to $115 but maintained an Overweight rating, implying substantial potential upside from recent levels. The target reduction reflects more conservative estimates rather than a bearish long-term view.
- Neutral Sentiment: Zoetis appointed James “Jay” Saccaro as executive vice president and chief financial officer, with the announcement also describing an expanded finance and operating leadership role. The change may improve execution, but its near-term effect on results is unclear. Zoetis Appoints Jay Saccaro
- Negative Sentiment: Second-quarter revenue was $2.47 billion, below the $2.50 billion consensus and essentially flat year over year. Management cited weaker veterinary traffic, customer price sensitivity and competitive pressure in companion-animal products, with promotions being used to defend market share. ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
- Negative Sentiment: Zoetis cut fiscal 2026 guidance to adjusted EPS of $6.15–$6.25 from expectations near $6.87, and revenue guidance to $9.1–$9.3 billion versus consensus of roughly $9.8 billion. The outlook reduction is the primary reason the stock has declined despite the quarterly earnings beat. Zoetis Q2 Earnings Beat Estimates, Revenues Miss, 2026 View Cut
Analysts Set New Price Targets
Several brokerages have commented on ZTS. Citigroup lowered their price objective on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. UBS Group reduced their target price on Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday. Barclays decreased their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a research note on Wednesday, July 1st. Wall Street Zen downgraded Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating on the stock in a research note on Friday, June 26th. Seven analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $115.50.
Check Out Our Latest Stock Report on Zoetis
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Read More
- Five stocks we like better than Zoetis
- Datadog’s Drop Says More About Expectations Than Earnings
- D-Wave’s Quantum Breakthrough Couldn’t Save QBTS From a Sell-Off
- Cloudflare’s Beat-and-Raise Quarter Puts Its AI Edge Story in Focus
- Solventum Nears Inflection Point As It Begins to Unlock Value
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
